Ahmed Koriesh on Comparison of Apixaban and Warfarin
Ahmed Koriesh, Director Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:
”How many patients have you seen with stroke or bleeding related to warfarin in LVAD patients?
A recent trial in LVAD patients compared apixaban with warfarin over 2 years:
Lower HRAEs (stroke, bleeding, thrombosis):
12.5% vs 43% (p=0.087)
Significantly fewer transfusions:
0.69 vs 4.82 EPPY (p<0.01)
Win ratio favored apixaban:
2.30 (95% CI 0.95–5.60)
Although underpowered, the signals consistently leaned toward apixaban with no excess thrombosis or mortality observed.
Bottom line:
Apixaban is showing a promise as a safe alternative to warfarin in selected LVAD patients — larger trials are needed before changing practice.”
Stay updated with Hemostasis Today.
-
May 23, 2026, 14:48Sam Zeraatain Nejad Davani: Off-Pump Surgery for COVID-19 Right Atrial Thrombosis
-
May 23, 2026, 14:42How Should Evidence Be Interpreted in Modern Hemophilia Care? – GARDEN
-
May 23, 2026, 12:52Fernanda Orsi: Honor to Be Speaking on ITP Diiferential Diagnosis at the 2026 Highlights of ASH
-
May 23, 2026, 12:46Jayagowri Karthikeyan: Grateful to Receive NBEMS President’s Gold Medal for Excellence In Immunohematology and Blood Transfusion
-
May 23, 2026, 12:40Aryabhatta Sadhu: Redefining Transfusion Medicine Across Obstetrics, Gynecology, and Fetal Medicine
-
May 23, 2026, 12:03Kiana Mohammadian: Do Anti-Inflammatory Cytokines Modulate Thrombosis?
-
May 23, 2026, 11:55Zikra Tazeen Mohammad Zakriya: Exploring the Link Between Vitamin D, Stroke, and Thrombosis
-
May 23, 2026, 11:33Alessandra Bosch: Swiss Delphi Consensus Study on Thrombophilia Testing Indications
-
May 23, 2026, 11:21Dip Ghosh: How CPDA-1 Keeps Transfusions Safe and Effective